Inclusion Criteria:~* Completed Study WN29922 or WN39658, either its double-blind part or OLE part, and did not
discontinue study drug early~* The participant should be capable of completing assessments either alone or with
the help of the caregiver~* Availability of a person (referred to as the caregiver)~* For women of childbearing
potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception methods
with a failure rate of <1% per year (bilateral tubal ligation, male sterilization, hormonal contraceptives that
inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the
treatment period and for at least 16 weeks after the final dose of gantenerumab~* Agreement not to donate blood
or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug~
